SYNAPSE Research Management Partners reposted this
The recommendation of lecanemab, the first disease-modifying therapy (DMT) for Alzheimer’s disease (AD), by the European Medicines Agency constitutes a major breakthrough for the dementia community. However, several steps still remain before patients can access these new treatments, which are bound to challenge European healthcare systems. A major remaining hurdle is overcoming pricing and reimbursement discussions which will take place within each individual country. Further, health care systems will need to address limited capacity of specialist services for diagnosis and treatment. Supporting clinicians with tools to help them identify the patients most likely to benefit from these new therapies is therefore vital to improve health systems readiness and ensure quality care for people with AD. Diagnosis and management of AD are challenging due to the high incidence of comorbidities, such as cardiovascular and psychiatric conditions. By considering individual differences in patients’ genetic makeup, lifestyles and clinical parameters, precision medicine has the potential to dramatically improve diagnosis, prognosis and treatment of AD. Considering these individual differences may help identify patients who may encounter adverse effects. Last year, we asked members of the European Alzheimer’s Disease Consortium (EADC) of memory clinics about challenges in determining a diagnosis and managing patient care. Their responses underscored the need for decision support systems in clinical practice. Read more: https://lnkd.in/eDrEqkZg Listen to Hanneke Rhodius- Meester, clinical Geriatrician at Amsterdam UMC & Oslo University Hospital about the development and use of our clinical decision support tool to improve diagnosis, communication, and shared decision-making for patients with memory-related issues. https://lnkd.in/eCmkxkGX Karolinska Institutet (Project Coordinator Linus Jönsson), Combinostics (Project Co-Coordinator Jyrki Lötjönen), SYNAPSE Research Management Partners, Alzheimer Europe, Region Stockholm, BioArctic, Uniklinik Köln, IHE - The Swedish Institute for Health Economics, Fundación Pasqual Maragall, CHU de Bordeaux, University Medical Centre Ljubljana, University of Eastern Finland, Amsterdam UMC, Amsterdam UMC - Alzheimer Center Amsterdam, FINGERS Brain Health Institute The Innovative Health Initiative (IHI) is a Joint Undertaking that receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA - European Federation of Pharmaceutical Industries and Associations, EuropaBio - the European Association for Bioindustries, MedTech Europe, Vaccines Europe, BioArctic AB and Combinostics Oy.
